Hegde, Meenakshi http://orcid.org/0000-0002-7778-7871
Navai, Shoba http://orcid.org/0000-0003-1220-2788
DeRenzo, Christopher
Joseph, Sujith K.
Sanber, Khaled http://orcid.org/0000-0002-8927-9786
Wu, Mengfen
Gad, Ahmed Z. http://orcid.org/0000-0002-6149-3414
Janeway, Katherine A.
Campbell, Matthew
Mullikin, Dolores
Nawas, Zeid http://orcid.org/0000-0001-6603-7664
Robertson, Catherine
Mathew, Pretty R.
Zhang, Huimin
Mehta, Birju
Bhat, Raksha R.
Major, Angela
Shree, Ankita
Gerken, Claudia
Kalra, Mamta
Chakraborty, Rikhia
Thakkar, Sachin G.
Dakhova, Olga
Salsman, Vita S.
Grilley, Bambi
Lapteva, Natalia
Gee, Adrian
Dotti, Gianpietro
Bao, Riyue http://orcid.org/0000-0002-6105-1704
Salem, Ahmed Hamed http://orcid.org/0000-0002-9261-1583
Wang, Tao http://orcid.org/0000-0003-1957-7160
Brenner, Malcolm K.
Heslop, Helen E. http://orcid.org/0000-0001-7049-7698
Wels, Winfried S. http://orcid.org/0000-0001-9858-3643
Hicks, M. John
Gottschalk, Stephen http://orcid.org/0000-0003-3991-7468
Ahmed, Nabil http://orcid.org/0000-0002-0982-8424
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA276684-01, K12CA090433, K12CA090433, 2T32HL092332-16, P30CA047904, 1U54CA232568-01)
V Foundation for Cancer Research
Cancer Prevention and Research Institute of Texas (CPRIT RP160283, CPRIT RP160283, CPRIT RP180785 CARMIT)
EIF | Stand Up To Cancer (SU2C-AACR-DT1113)
Article History
Received: 23 December 2022
Accepted: 23 February 2024
First Online: 24 April 2024
Competing interests
: M.H., S.K.J., V.S.S., S.G. and N.A. are named inventors on patent applications in the field of CAR T cell therapy owned by BCM. C.D. has a patent and patent applications in the field of cell and gene therapy for cancer. K.A.J. is a consultant for Bayer, Illumina and Ipsen. B.G. owns QB Regulatory Consulting, LLC, which has consulting agreements with TESSA Therapeutics, Marker Therapeutics, LOKON Pharma, AlloVir and Proxima. N.L. is a consultant with Tessa Therapeutics. M.K.B. has equity in Allovir, Marker Therapeutics and Tessa Therapeutics, has served on advisory boards for Walking Fish Therapeutics, CellGenix, Marker Therapeutics, Tessa Therapeutics, Abintus, Allogene, Bellicum Pharmaceuticals, Bluebird Bio, Athenex, Memgen, Turnstone Biologics, Coya Therapeutics, TScan Therapeutics, Onkimmune, Poseida Therapeutics and Allovir and has received research support from Tessa Therapeutics. H.E.H. has equity in Allovir and Marker Therapeutics, has served on advisory boards for Tessa Therapeutics, Novartis, Gilead, GSK, Kiadis and Fresh Wind Biotechnologies and has received research support from Tessa Therapeutics and Kuur Therapeutics. S.G. has patent applications in the fields of natural killer cell and T cell and/or gene therapy for cancer. S.G. is also a consultant of Tessa Therapeutics, a Data and Safety Monitoring Board member of Immatics, and has received honoraria from Tidal, Catamaran Bio, Sanofi and Novartis within the last 2 years. N.A. received one-time royalties from Celgene and Cell Medica, consulted in the past for Adaptimmune and continues to consult for Equillium (pro bono) and The Children’s Cancer Hospital Egypt 57357. None of these relationships conflict with the published work. The other authors declare no competing interests.